Genfit’s 2025 Mid-Year Financial and Strategic Update

Genfit ( (GNFT) ) has released its Q2 earnings. Here is a breakdown of the information Genfit presented to its investors.

Genfit is a French biopharmaceutical company focused on discovering and developing innovative drug candidates and diagnostic solutions, primarily targeting metabolic and liver diseases. In its latest earnings report for the first half of 2025, Genfit highlighted several key developments, including the approval of Iqirvo® (elafibranor) pricing and reimbursement in Italy, marking a significant milestone in its collaboration with Ipsen. The company also secured a non-dilutive royalty financing agreement with HealthCare Royalty, providing substantial financial backing for its ongoing projects.

Financially, Genfit reported a decrease in revenues to €33.5 million from €59 million in the same period last year, attributed to lower milestone payments. The company faced a net loss of €10 million, a significant downturn from a net profit of €30 million in the previous year. This was largely due to increased research and development expenses and financial charges related to the royalty financing. Despite these challenges, Genfit’s cash position improved, with cash and equivalents rising to €107.5 million.

Strategically, Genfit made notable progress with its Iqirvo® product, achieving key milestones that triggered significant payments from Ipsen. However, the company faced setbacks with its Versantis VS-01 program, leading to a strategic pivot away from ACLF towards UCD development. This decision will result in a full impairment of the VS-01 intangible asset in the second half of 2025.

Looking ahead, Genfit’s management remains focused on leveraging its strengthened financial position to advance its pipeline and explore new opportunities in the biopharmaceutical sector. The company is poised to navigate the challenges and opportunities in the market with a strategic focus on innovation and collaboration.